{"disease":{"id":"opioid","name":"opioid"},"drugs":{"marketed":[{"drug_id":"buprenorphine","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"buprenorphine","indication_name":"Opioid dependence","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"buprenorphine","indication_name":"Prevention of opioid abuse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"buprenorphine","indication_name":"Opioid Dependence Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Prevention of opioid abuse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Opioid dependence","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"methylnaltrexone","indication_name":"Therapeutic opioid induced constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Relistor","generic_name":"METHYLNALTREXONE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":69,"revenue":"400","mechanism":"Relistor works by blocking opioid receptors in the gut to alleviate constipation."},{"drug_id":"fentanyl-f2","indication_name":"Breakthrough Pain in Opioid Tolerant Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"oxycodone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OxyContin","generic_name":"oxycodone","company_name":"Purdue Pharma","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"naloxone-hydrochloride","indication_name":"Management of pain severe enough to require an opioid analgesic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naloxone Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Opioid receptors (mu, kappa)","drug_class":"Mixed opioid agonist-antagonist with opioid antagonist","quality_score":70,"revenue":null,"mechanism":"Pentazocine is a mixed agonist-antagonist at opioid receptors; naloxone is an opioid antagonist."},{"drug_id":"naltrexon","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Prevention of opioid abuse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Therapeutic opioid induced constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methadone","indication_name":"Opioid withdrawal","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methadone Hydrochloride","generic_name":"METHADONE","company_name":"Specgx Llc","drug_phase":"marketed","molecular_target":"mu-opioid receptors, NMDA receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Methadone is a synthetic opioid that acts as a mu-agonist, providing analgesia and aiding in opioid addiction management."},{"drug_id":"levomethadone","indication_name":"Opioid dependence","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LEVOMETHADONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"levomethadone","quality_score":null,"revenue":null,"mechanism":"LEVOMETHADONE works by binding to opioid receptors in the brain, reducing withdrawal symptoms and cravings."},{"drug_id":"fentanyl","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"fentanyl","indication_name":"Breakthrough Pain in Opioid Tolerant Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"morphine","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"movantik","indication_name":"Therapeutic opioid induced constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Movantik","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"benzhydrocodone","indication_name":"Short-term management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BENZHYDROCODONE","company_name":"","drug_phase":"marketed","molecular_target":"Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways","drug_class":"Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic","quality_score":75,"revenue":null,"mechanism":"Benzhydrocodone is a hydrocodone prodrug providing mu-opioid receptor agonism combined with acetaminophen's central analgesic activity."},{"drug_id":"morphine-sulfate","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"oxymorphone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oxymorphone","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"naloxegol","indication_name":"Therapeutic opioid induced constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Movantik","generic_name":"NALOXEGOL","company_name":"Averitas","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":65,"revenue":null,"mechanism":"Movantik works by blocking the mu-type opioid receptor, which is responsible for the constipating effects of opioids."},{"drug_id":"levomethadyl-acetate","indication_name":"Opioid dependence","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orlaam","generic_name":"LEVOMETHADYL ACETATE","company_name":"Roxane","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"lofexidine","indication_name":"Opioid withdrawal","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lucemyra","generic_name":"LOFEXIDINE","company_name":"Biocorrx Pharms","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"lofexidine","quality_score":null,"revenue":null,"mechanism":"Lucemyra works by activating the alpha-2A adrenergic receptor to reduce the release of norepinephrine, a neurotransmitter involved in withdrawal symptoms."},{"drug_id":"oxycontin","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OXYCONTIN®","company_name":"Mundipharma (China) Pharmaceutical Co. Ltd","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"OxyContin is a medication that works by binding to opioid receptors in the brain, altering the way the body perceives pain."},{"drug_id":"naldemedine","indication_name":"Opioid-induced constipation (OIC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symproic","generic_name":"NALDEMEDINE","company_name":"Bdsi","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":75,"revenue":null,"mechanism":"Symproic works by blocking the mu-type opioid receptor, which is responsible for slowing down bowel movements."},{"drug_id":"methadon","indication_name":"Opioid withdrawal","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methadon","company_name":"University of Utah","drug_phase":"discontinued","molecular_target":"Neuronal acetylcholine receptor subunit alpha-10, D(4) dopamine receptor, D(3) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"methadone","indication_name":"Temporary Treatment of Opioid Dependence","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methadone Hydrochloride","generic_name":"METHADONE","company_name":"Specgx Llc","drug_phase":"marketed","molecular_target":"mu-opioid receptors, NMDA receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Methadone is a synthetic opioid that acts as a mu-agonist, providing analgesia and aiding in opioid addiction management."},{"drug_id":"acetylmethadol","indication_name":"Opioid dependence","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methadyl","generic_name":"acetylmethadol","company_name":"","drug_phase":"unknown","molecular_target":"Mu-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Methadyl works by blocking potassium channels in the brain to stabilize neuronal activity and reduce withdrawal symptoms."},{"drug_id":"hydromorphone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"hydromorphone","indication_name":"Severe Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"naloxone","indication_name":"Opioid dependence","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Narcan","generic_name":"NALOXONE","company_name":"Adapt","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"naloxone","indication_name":"Prevention of opioid abuse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Narcan","generic_name":"NALOXONE","company_name":"Adapt","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"naldemedine","indication_name":"Therapeutic opioid induced constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symproic","generic_name":"NALDEMEDINE","company_name":"Bdsi","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":75,"revenue":null,"mechanism":"Symproic works by blocking the mu-type opioid receptor, which is responsible for slowing down bowel movements."}],"pipeline":[],"offLabel":[],"totalMarketed":41,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03743493","title":"PCORnet Opioid Surveillance Study","phase":"","overall_status":"COMPLETED","enrollment_count":15438284,"lead_sponsor_name":"Louisiana Public Health Institute","has_results":false},{"nct_id":"NCT03407638","title":"PRimary Care Opioid Use Disorders Treatment (PROUD) Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":973759,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT02662153","title":"Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics","phase":"","overall_status":"COMPLETED","enrollment_count":808455,"lead_sponsor_name":"Member Companies of the Opioid PMR Consortium","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT03198208","title":"Intraoperative Fentanyl Dose on Respiratory Complications","phase":"","overall_status":"UNKNOWN","enrollment_count":183396,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02668549","title":"Cross-Sectional Study to Define and Validate \"Doctor/Pharmacy Shopping\" as Outcomes Suggestive of Abuse and/or Addiction","phase":"","overall_status":"COMPLETED","enrollment_count":164923,"lead_sponsor_name":"Member Companies of the Opioid PMR Consortium","has_results":false},{"nct_id":"NCT04944225","title":"Opioid Reduction Strategy South Western Ontario","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT05745480","title":"Natural Language Processing for Screening Opioid Misuse","phase":"","overall_status":"COMPLETED","enrollment_count":47502,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT06768814","title":"Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data","phase":"NA","overall_status":"RECRUITING","enrollment_count":40000,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT04418453","title":"Rural MOUD Telemedicine in Primary Care Phase 1","phase":"","overall_status":"COMPLETED","enrollment_count":36762,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT03720613","title":"Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation","phase":"","overall_status":"RECRUITING","enrollment_count":34532,"lead_sponsor_name":"BioDelivery Sciences International","has_results":false},{"nct_id":"NCT04805229","title":"A Difference-In-Differences Analysis of New Persistent Opioid Use After Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":30000,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT05944133","title":"Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27257,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT05358522","title":"Increasing Implementation of Post-Operative Opioid Prescribing Guidelines","phase":"NA","overall_status":"COMPLETED","enrollment_count":26562,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT04446975","title":"Best Practice Alert for Opioid Prescribing","phase":"NA","overall_status":"COMPLETED","enrollment_count":21689,"lead_sponsor_name":"University of Colorado, Denver","has_results":true},{"nct_id":"NCT04878562","title":"I-COPE Study: Opioid Use and Pain Management in Older Adults","phase":"NA","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT05160233","title":"Digital Treatments for Opioids and Other Substance Use Disorders in Primary Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":18430,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT04499079","title":"Alliances to Disseminate Addiction Prevention and Treatment (ADAPT)","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":12400,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT04628832","title":"Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms","phase":"NA","overall_status":"COMPLETED","enrollment_count":12000,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT04198428","title":"Clinical Decision Support for Opioid Use Disorders in Medical Settings (COMPUTE 2.0)","phase":"NA","overall_status":"COMPLETED","enrollment_count":10891,"lead_sponsor_name":"HealthPartners Institute","has_results":true},{"nct_id":"NCT05877157","title":"Pain AND Opioids After Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"University of Aberdeen","has_results":false},{"nct_id":"NCT02813356","title":"Naloxegol US PMR CV Safety.","phase":"","overall_status":"UNKNOWN","enrollment_count":8800,"lead_sponsor_name":"Valinor Pharma LLC","has_results":false},{"nct_id":"NCT04632238","title":"Coaching Performance Driven Practice Change in the Context of Value Based Purchasing Under New York Medicaid","phase":"NA","overall_status":"COMPLETED","enrollment_count":7950,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT06443385","title":"E-mails to Nudge Safer and Better-Informed Prescribing of Risky Drugs","phase":"NA","overall_status":"COMPLETED","enrollment_count":7872,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT06008496","title":"Patient Reported Outcomes, Postoperative Pain and Pain Relief After Day Case Surgery (POPPY)","phase":"","overall_status":"COMPLETED","enrollment_count":7839,"lead_sponsor_name":"University Hospital Plymouth NHS Trust","has_results":false},{"nct_id":"NCT03568552","title":"Patient Decision Aid for Opioid Use Disorder","phase":"NA","overall_status":"COMPLETED","enrollment_count":7554,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT07466784","title":"CEDRN: Opioid Registry","phase":"","overall_status":"RECRUITING","enrollment_count":7200,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT05072249","title":"European Cohort Study of the Effectiveness of Take Home Naloxone","phase":"","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT04296396","title":"Opioid Prescription After Cesarean Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5521,"lead_sponsor_name":"The George Washington University Biostatistics Center","has_results":true},{"nct_id":"NCT03932799","title":"Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing","phase":"","overall_status":"COMPLETED","enrollment_count":5411,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT06292078","title":"Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)","phase":"NA","overall_status":"RECRUITING","enrollment_count":5076,"lead_sponsor_name":"University of Oregon","has_results":false},{"nct_id":"NCT03658642","title":"Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD","phase":"NA","overall_status":"COMPLETED","enrollment_count":5047,"lead_sponsor_name":"Yale University","has_results":true},{"nct_id":"NCT06523985","title":"The Feasibility of Using the PulsePoint to Facilitate Overdose Education and Naloxone Distribution","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5000,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT05387408","title":"Improving Health and Employment Outcomes Through Workplace Opioid Policies","phase":"NA","overall_status":"COMPLETED","enrollment_count":4939,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT06593353","title":"Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail","phase":"NA","overall_status":"RECRUITING","enrollment_count":4165,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06429436","title":"Vending Machine Naloxone Distribution for Your Community (VENDY)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT05900791","title":"Persistent Pain After Knee Replacement","phase":"","overall_status":"COMPLETED","enrollment_count":3710,"lead_sponsor_name":"University Hospital Bispebjerg and Frederiksberg","has_results":false},{"nct_id":"NCT06965010","title":"Measurement Based Care in Opioid Treatment Programs","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3650,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT02751762","title":"A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Opioids for the Treatment of Chronic Pain","phase":"","overall_status":"COMPLETED","enrollment_count":3600,"lead_sponsor_name":"Member Companies of the Opioid PMR Consortium","has_results":false},{"nct_id":"NCT06743178","title":"The Effects of Mass Media Photographs on Drug-Related Stigma","phase":"NA","overall_status":"COMPLETED","enrollment_count":3570,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT07317869","title":"Impact Evaluation of the Therapeutic Initiative's Prescribing Portrait and Therapeutics Letter on Opioid Use by Dentists","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":3498,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT07024498","title":"Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":3492,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT04216719","title":"Facilitating Opioid Care Connections","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3440,"lead_sponsor_name":"New York State Psychiatric Institute","has_results":false},{"nct_id":"NCT03396276","title":"Houston Emergency Opioid Engagement System","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":false},{"nct_id":"NCT05845177","title":"Persistent Pain After Hip Replacement","phase":"","overall_status":"COMPLETED","enrollment_count":2777,"lead_sponsor_name":"University Hospital Bispebjerg and Frederiksberg","has_results":false},{"nct_id":"NCT02667197","title":"Study to Validate Coded Medical Terms Used to Identify Opioid-Related Overdose in Databases Used for PMR Study 1B","phase":"","overall_status":"COMPLETED","enrollment_count":2701,"lead_sponsor_name":"Member Companies of the Opioid PMR Consortium","has_results":false},{"nct_id":"NCT05678036","title":"Effects on Mortality and Clinical Course of a Patient's Choice Model for Opioid Maintenance Treatment for Opioid Dependence - Evaluation of a System Enabling a Large Expansion of Treatment Providers and Treatment Access","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Region Skane","has_results":false},{"nct_id":"NCT04971902","title":"Pharmacist-led Pharmacogenomic Clinical Service Within the Program of All-inclusive Care for the Elderly","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Tabula Rasa HealthCare","has_results":false},{"nct_id":"NCT07224711","title":"The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":2290,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT03887247","title":"Reducing Concurrent Opioid-Benzodiazepine Prescriptions","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2234,"lead_sponsor_name":"Walter Reed National Military Medical Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}